1. Sorbera LA, Serradell N, Bolos J, Bayes M. Terutroban sodium.
Prostanoid tp receptor antagonist, antithrombotic agent, antiatherosclerotic
agent. Drugs Future. 2006;31:867–73.
2. Fiessinger JN. S18886, a new specific TP-receptor antagonist, is
safe and as effective as aspirin in inhibiting platelet aggregation in
patients with peripheral arterial disease. Eur Heart J. 2004;25:573.
3. Bousser MG, Amarenco P, Chamorro A, et al. Rationale and
design of a randomized, double-blind, parallel-group study of
terutroban 30 mg/day versus aspirin 100 mg/day in stroke
patients: the Prevention of cerebrovascular and cardiovascular
Events of ischemic origin with teRutroban in patients with a
history oF ischemic strOke or tRansient ischeMic attack (PERFORM)
study. Cerebrovasc Dis. 2009;27:509–18.
4. Bousser MG, Amarenco P, Chamorro A, et al. The Prevention of
cerebrovascular and cardiovascular Events of ischemic origin with
teRutroban in patients with a history oF ischemic strOke or
tRansient ischeMic attack (PERFORM) study: baseline characteristics
of the population. Cerebrovasc Dis. 2009;27:608–13.
5. Cheng Y, Austin SC, Rocca B, et al. Role of prostacyclin in the cardiovascular
response to thromboxane A2. Science. 2002;296:539–41.
6. Cayatte AJ, Du Y, Oliver-Krasinski J, Lavielle G, Verbeuren TJ,
Cohen RA. The thromboxane receptor antagonist S18886 but not
aspirin inhibits atherogenesis in apo E-deficient mice: evidence
that eicosanoids other than thromboxane contribute to atherosclerosis.
Arterioscler Thromb Vasc Biol. 2000;20:1724–8.
7. Egan KM, Wang M, Fries S, et al. Cyclooxygenases, thromboxane,
and atherosclerosis: plaque destabilization by cyclooxygenase-2
inhibition combined with thromboxane receptor antagonism. Circulation.
2005;111:334–42.
8. Viles Gonzalez JF, Fuster V, Corti R, et al. Atherosclerosis
regression and TP receptor inhibition: effect of S18886 on plaque
size and composition—a magnetic resonance imaging study. Eur
Heart J. 2005;26:1557–61.
9. Worth NF, Berry CL, Thomas AC, Campbell JH. S18886, a
selective TP receptor antagonist, inhibits development of atherosclerosis
in rabbits. Atherosclerosis. 2005;183:65–73.
10. Belhassen L, Pelle G, Dubois Rande JL, Adnot S. Improved
endothelial function by the thromboxane A2 receptor antagonist
S18886 in patients with coronary artery disease treated with
aspirin. J Am Coll Cardiol. 2003;41:1198–204.
11. O’Leary DH, Polak JF, Kronmal RA, Manolio TA, Burke GL,
Wolfson Jr SK. Carotid-artery intima and media thickness as a risk
factor for myocardial infarction and stroke in older adults.
Cardiovascular Health Study Collaborative Research Group. N
Engl J Med. 1999;340:14–22.
12. Bots ML, Hoes AW, Koudstaal PJ, Hofman A, Grobbee DE.
Common carotid intima-media thickness and risk of stroke and
myocardial infarction: the Rotterdam Study. Circulation. 1997;96:
1432–7.
13. Chambless LE, Heiss G, Folsom AR, et al. Association of coronary
heart disease incidence with carotid arterial wall thickness and major
risk factors: the Atherosclerosis Risk in Communities (ARIC) Study,
1987–1993. Am J Epidemiol. 1997;146:483–94.
14. Chambless LE, Folsom AR, Clegg LX, et al. Carotid wall
thickness is predictive of incident clinical stroke: the Atherosclerosis
Risk in Communities (ARIC) study. Am J Epidemiol.
2000;151:478–87.
15. Lorenz MW, Markus HS, Bots ML, Rosvall M, Sitzer M.
Prediction of clinical cardiovascular events with carotid intimamedia
thickness: a systematic review and meta-analysis. Circulation.
2007;115:459–67.
16. Touboul PJ, Hennerici MG, Meairs S, et al. Mannheim carotid
intima-media thickness consensus (2004–2006). An update on
behalf of the Advisory Board of the 3rd and 4th Watching the
Risk Symposium, 13th and 15th European Stroke Conferences,
Mannheim, Germany, 2004, and Brussels, Belgium, 2006.
Cerebrovasc Dis. 2007;23:75–80.
17. Zureik M, Ducimetiere P, Touboul PJ, et al. Common carotid
intima-media thickness predicts occurrence of carotid atherosclerotic
plaques: longitudinal results from the Aging Vascular Study
(EVA) study. Arterioscler Thromb Vasc Biol. 2000;20:1622–9.
18. Amarenco P, Labreuche J, Lavallee P, Touboul PJ. Statins in
stroke prevention and carotid atherosclerosis: systematic review
and up-to-date meta-analysis. Stroke. 2004;35:2902–9.
19. Kodama M, Yamasaki Y, Sakamoto K, et al. Antiplatelet drugs
attenuate progression of carotid intima-media thickness in subjects
with type 2 diabetes. Thromb Res. 2000;97:239–45.
20. Pitt B, Byington RP, Furberg CD, et al. Effect of amlodipine on
the progression of atherosclerosis and the occurrence of clinical
events. PREVENT Investigators. Circulation. 2000;102:1503–10.
21. Crouse III JR, Raichlen JS, Riley WA, et al. Effect of rosuvastatin
on progression of carotid intima-media thickness in low-risk
individuals with subclinical atherosclerosis: the METEOR Trial.
JAMA. 2007;297:1344–53.
22. Liang Q, Wendelhag I, Wikstrand J, Gustavsson T. A multiscale
dynamic programming procedure for boundary detection in
ultrasonic artery images. IEEE Trans Med Imaging. 2000;19:
127–42.
23. Dogan S, Meijer R, Grobbee DE, et al. Assessment of carotid
plaque progression with ultrasound in a low-risk population.
Presented at the International Symposium on Atherosclerosis,
Boston, Mass, USA. 2009.
24. Paini A, Boutouyrie P, Calvet D, Tropeano AI, Laloux B, Laurent
S. Carotid and aortic stiffness: determinants of discrepancies.
Hypertension. 2006;47:371–6.
25. Van Bortel LM, Balkestein EJ, van der Heijden-Spek JJ, et al.
Non-invasive assessment of local arterial pulse pressure: comparison
of applanation tonometry and echo-tracking. J Hypertens.
2001;19:1037–44.
26. Laurent S, Cockcroft J, Van BL, et al. Expert consensus document
on arterial stiffness: methodological issues and clinical applications.
Eur Heart J. 2006;27:2588–605.
References
References